P A Meyers

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era
    Trang H La
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 64:544-50. 2006
  2. pmc Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
    BMC Cancer 8:124. 2008
  3. ncbi request reprint High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis
    P A Meyers
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 19:2812-20. 2001
  4. ncbi request reprint Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
  5. ncbi request reprint High-dose therapy with autologous stem cell rescue for pediatric sarcomas
    Paul A Meyers
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Oncol 16:120-5. 2004
  6. ncbi request reprint Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults
    E Anders Kolb
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, PO Box 139, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3423-30. 2003
  7. doi request reprint Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group
    Paul A Meyers
    Children s Oncology Group, Arcadia, CA, USA
    J Clin Oncol 26:633-8. 2008
  8. doi request reprint Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
    Paul A Meyers
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Anticancer Ther 9:1035-49. 2009
  9. pmc Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:1736-44. 2011
  10. ncbi request reprint Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol
    P A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:2452-8. 1998

Detail Information

Publications59

  1. ncbi request reprint Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era
    Trang H La
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 64:544-50. 2006
    ..To evaluate the outcomes of patients with Ewing's sarcoma family of tumors (ESFT) treated with modern radiotherapy techniques with MRI along with optimal chemotherapy...
  2. pmc Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
    BMC Cancer 8:124. 2008
    ..Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied...
  3. ncbi request reprint High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis
    P A Meyers
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 19:2812-20. 2001
    ....
  4. ncbi request reprint Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
    ....
  5. ncbi request reprint High-dose therapy with autologous stem cell rescue for pediatric sarcomas
    Paul A Meyers
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Oncol 16:120-5. 2004
    ..This review evaluates the results of high dose therapy with stem cell reconstitution used to consolidate treatment of high risk patients with sarcomas...
  6. ncbi request reprint Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults
    E Anders Kolb
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, PO Box 139, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3423-30. 2003
    ..To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy...
  7. doi request reprint Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group
    Paul A Meyers
    Children s Oncology Group, Arcadia, CA, USA
    J Clin Oncol 26:633-8. 2008
    ..To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma...
  8. doi request reprint Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
    Paul A Meyers
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Expert Rev Anticancer Ther 9:1035-49. 2009
    ..Mifamurtide has been approved in Europe for the treatment of newly diagnosed osteosarcoma in combination with chemotherapy...
  9. pmc Addition of pamidronate to chemotherapy for the treatment of osteosarcoma
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:1736-44. 2011
    ..This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma...
  10. ncbi request reprint Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol
    P A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:2452-8. 1998
    ..The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS...
  11. ncbi request reprint High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors
    B H Kushner
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3016-20. 1998
    ..To help fill the gap in knowledge about the risk of leukemia from repetitive high-dose use of alkylating agents and topoisomerase-II inhibitors in young patients with solid tumors...
  12. ncbi request reprint The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma
    J S Wunder
    Department of Surgery, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York City, NY 10021, USA
    J Bone Joint Surg Am 80:1020-33. 1998
    ..These indicators should be used to identify patients who are at high risk for metastasis as such patients may be candidates for more intensive or novel therapies...
  13. ncbi request reprint How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:870-80. 2001
    ..We now present results achieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as reported in the literature...
  14. ncbi request reprint The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience
    Susan N Chi
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 42:46-51. 2004
    ..To further investigate this hypothesis, the relapse patterns among groups receiving chemotherapy regimens of variable intensity at Memorial Sloan-Kettering Cancer Center were analyzed...
  15. pmc Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group
    Smita Bhatia
    Division of Pediatric Oncology, City of Hope National Medical Center, Duarte, CA, USA
    Blood 109:46-51. 2007
    ..Increasing exposure to ifosfamide from 90 to 140 g/m2, cyclophosphamide from 9.6 to 17.6 g/m2, and doxorubicin from 375 to 450 mg/m2 increased the risk of t-MDS/AML significantly...
  16. pmc Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group
    Alexander J Chou
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 115:5339-48. 2009
    ..The authors report the results of addition of liposomal MTP-PE to chemotherapy for patients with metastatic OS...
  17. ncbi request reprint Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma
    R Gorlick
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 7:3065-70. 2001
    ..99m)Tc-MIBI imaging did not correlate with measures of P-glycoprotein expression in the tumor tissue...
  18. ncbi request reprint Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:468-74. 2000
    ..We tested the hypothesis that much higher dosing would meet critical goals of salvage therapy: antitumor effect and a lack of toxicity to key organs, so as not to preclude subsequent consolidative treatments needed for cure...
  19. ncbi request reprint Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia
    Peter G Steinherz
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Hematol Oncol 29:656-8. 2007
    ..The remissions were sustained with repeated cycles of monotherapy for 47, 59, and 64 weeks, respectively...
  20. ncbi request reprint Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma
    LeLe Aung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:342-8. 2003
    ..We investigated the incidence and outcome of metachronous skeletal OS after initial treatment of the primary tumor...
  21. ncbi request reprint Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, SM07, New York, NY 10021, USA
    Cancer 97:179-85. 2003
    ..The authors evaluated the outcome of patients with rhabdomyosarcoma (RMS) who were treated with three-dimensional (3D) conformal radiation therapy (RT) at a single institution...
  22. ncbi request reprint Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific
    Richard Gorlick
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 25:840-1. 2003
  23. ncbi request reprint Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 61:1432-8. 2005
    ..To determine the preliminary results of intensity-modulated radiotherapy (IMRT) for head-and-neck rhabdomyosarcoma...
  24. ncbi request reprint Ewing's sarcoma in a patient with congenital optic atrophy
    C Fein Levy
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 20:577-9. 1998
    ..However, she continues to have deterioration of her visual acuity. CONCLUSION: This report of cancer in a child with dominant optic atrophy suggests the possible need for a higher degree of suspicion of malignancy in these patients...
  25. ncbi request reprint Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience
    Alexander J Chou
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2214-21. 2005
    ..Overall survival after recurrence of osteosarcoma (OS) is < 30%. The authors reported their experience treating recurrent OS at the time of first recurrence (R1)...
  26. ncbi request reprint Methotrexate levels and outcome in osteosarcoma
    Shayna Zelcer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 44:638-42. 2005
    ..The goal of the study was to assess whether there is a correlation between histologic necrosis of the tumor and/or prognosis with peak MTX serum concentration...
  27. ncbi request reprint Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia
    P A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Cancer 64:2416-9. 1989
    ..Although AZQ and AAFC are active in childhood ANLL with acceptable toxicity, the combination does not appear more active than AZQ used alone. Future studies should define the role of AZQ in combination with other agents...
  28. ncbi request reprint Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
    ..Recurrent osteosarcoma is a drug-resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET-743) as a salvage therapy in these patients...
  29. ncbi request reprint Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience
    Maura Cosetti
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Pediatr Hematol Oncol 24:101-5. 2002
    ..This report describes an institutional experience with irinotecan for the treatment of pediatric solid tumors...
  30. ncbi request reprint Leydig cell tumor after treatment for Ewing's sarcoma
    Linda J Butros
    Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
    Pediatr Blood Cancer 49:1008-10. 2007
    ..Additional monitoring for second malignancies may become appropriate as long-term survival continues to improve for patients with Ewing's sarcoma...
  31. ncbi request reprint Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma
    Bang H Hoang
    Department of Surgery, Orthopaedic Surgery Service, affiliated with Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 109:106-11. 2004
    ..These results showed that expression of LRP5 is a common event in OS and strongly suggest a role for LRP and Wnt signaling in the pathobiology and progression of this disease...
  32. doi request reprint Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma
    Heather Magnan
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:4147-51. 2010
    ..In the current study, the authors re-examined a series of patients studied using Tl-201 scintigraphy to determine the correlation between changes observed on Tl-201 scintigraphy and event-free survival (EFS)...
  33. doi request reprint Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience
    Denise A Casey
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 53:1029-34. 2009
    ..A pediatric phase I trial has shown this regimen to be safe and active in advanced ES...
  34. ncbi request reprint Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples
    Rui Yang
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:837-44. 2003
    ..Additional studies are under way to determine the clinical significance of these sequence alterations and their effect on methotrexate transport and resistance...
  35. ncbi request reprint Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY, USA
    Int J Cancer 121:943-54. 2007
    ..This study suggests that PTHR1 over-expression may promote osteosarcoma progression by conferring a more aggressive phenotype, and forming a more favorable microenvironment...
  36. ncbi request reprint mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma
    Rebecca Sowers
    Department of Pediatrics, Orthopaedic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cancer Ther 2:535-41. 2003
    ....
  37. ncbi request reprint The challenging role of radiation therapy for very young children with rhabdomyosarcoma
    Dev R Puri
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 65:1177-84. 2006
    ..To evaluate local control and toxicity for very young children treated with multimodality therapy for rhabdomyosarcoma (RMS)...
  38. doi request reprint Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
    Tadahiko Kubo
    Orthopedic Surgery Service, Memorial Sloan Kettering Cancer Center, Weil Medical College of Cornell University, New York, New York, USA
    Cancer 112:2119-29. 2008
    ....
  39. ncbi request reprint PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools
    Michelle L Klem
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pediatr Hematol Oncol 29:9-14. 2007
    ..Complete staging of rhabdomyosarcoma is critical to deliver appropriate therapy. We evaluated the role of F-fluorodeoxyglucose positron emission tomography (PET) in the staging of patients with rhabdomyosarcoma...
  40. ncbi request reprint Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging
    Jonathan P Dyke
    Department of Radiology, Weill Medical College of Cornell University, 1300 York Ave, Box 234, New York, NY 10021 4885, USA
    Radiology 228:271-8. 2003
    ..The ability to determine response to induction chemotherapy by means of noninvasive monitoring of necrotic fraction with perfusion MR imaging methods may provide useful prognostic information and help surgical planning...
  41. ncbi request reprint Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience
    LeLe Aung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1728-34. 2002
    ..The authors investigated the incidence and relative risk of secondary malignant neoplasms in long-term survivors of osteosarcoma...
  42. ncbi request reprint Radiotherapy in the multimodal treatment of extrarenal extracranial malignant rhabdoid tumors
    Dev R Puri
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:167-9. 2008
    ..Our limited experience suggests that RT in the setting of CMT and surgery has the potential to prolong survival with acceptable toxicity, but outcomes are inconsistent and further study is necessary...
  43. ncbi request reprint Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 11:2561-7. 2005
    ..To determine if osteosarcoma cells express chemokine receptors and if their presence or absence relates to clinical features...
  44. ncbi request reprint Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway
    Bang H Hoang
    Department of Surgery, Orthopaedic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 64:2734-9. 2004
    ..Taken together, these results support a possible role for Wnt signaling in the pathobiology and progression of human OS...
  45. ncbi request reprint Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma
    Ching C Lau
    Department of Pediatrics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Genes Chromosomes Cancer 39:11-21. 2004
    ....
  46. doi request reprint Primary desmoplastic small round cell tumor of the femur
    Akihiko Yoshida
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Skeletal Radiol 37:857-62. 2008
    ..This is the second reported case of primary DSRCT of bone with genetic confirmation...
  47. pmc Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study
    Jill P Ginsberg
    Division of Oncology, Department of Pediatrics, The Children s Hospital of Philadelphia, University of Pennsylvania, School of Medicine, Colket Translational Research Bldg, 3501 Civic Center Blvd, 10th Floor, Philadelphia, PA 19104, USA
    J Natl Cancer Inst 102:1272-83. 2010
    ..The survival of Ewing sarcoma (ES) patients has improved since the 1970s but is associated with considerable future health risks...
  48. doi request reprint The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue
    Shayna Zelcer
    Department of Pediatrics, Division of Hematology Oncology, Children s Hospital of Western Ontario, London, Ontario, Canada
    Pediatr Blood Cancer 50:1176-80. 2008
    ..We describe the safety and feasibility of an outpatient high dose methotrexate (HDMTX) regimen...
  49. ncbi request reprint An expression signature classifies chemotherapy-resistant pediatric osteosarcoma
    Michelle B Mintz
    Neurogenomics Division and Genetic Basis of Human Disease Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA
    Cancer Res 65:1748-54. 2005
    ..We propose that osteosarcoma tumor-driven changes in the bone microenvironment contribute to the chemotherapy-resistant phenotype and offer testable hypotheses to potentially enhance therapeutic response...
  50. ncbi request reprint Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone
    Holcombe E Grier
    Department of Pediatric Hematology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    N Engl J Med 348:694-701. 2003
    ..We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease...
  51. ncbi request reprint Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study
    James S Miser
    City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    J Clin Oncol 22:2873-6. 2004
    ....
  52. ncbi request reprint High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission
    Neyssa Marina
    J Clin Oncol 23:4262-4. 2005
  53. ncbi request reprint Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis
    Saminathan S Nathan
    Department of Orthopaedics, Faculty of Medicine, National University of Singapore, Singapore, USA
    Cancer 107:1607-16. 2006
    ..The prognostic factors in locally recurrent osteosarcoma were investigated and these factors were translated into a management strategy...
  54. ncbi request reprint Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943
    Nita L Seibel
    Hematology Oncology, Children s National Medical Center, George Washington University School of Medicine, Washington, DC 20010, USA
    Cancer 109:1646-53. 2007
    ....
  55. ncbi request reprint The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, New York 10467, USA
    Clin Cancer Res 13:2557-67. 2007
    ..Although defective RFC-mediated transport was frequently identified as a mechanism of methotrexate (MTX) resistance in osteosarcoma, the status of FR and its role in this disease are unknown...
  56. ncbi request reprint Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group
    James S Miser
    Division of Pediatrics, Department of Pediatric Hematology Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
    Pediatr Blood Cancer 49:894-900. 2007
    ..We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis...
  57. ncbi request reprint Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group
    Mark L Bernstein
    Hopital Sainte Justine, Hematology Oncology, Montreal Quebec, Canada
    J Clin Oncol 24:152-9. 2006
    ..We studied topotecan alone and combined with cyclophosphamide in therapeutic windows before the five-drug therapy. A randomly assigned proportion of patients received amifostine as a cytoprotective agent...
  58. ncbi request reprint Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration
    Jaime Morales-Arias
    Division of Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1568-77. 2007
    ..Whether ES cells and patient tumor samples express G-CSF and its receptor (G-CSFR) and whether treatment with this factor enhances tumor growth was examined...
  59. ncbi request reprint Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patients
    Jennifer Yu
    Robert Wood Johnson Medical School, Piscataway, New Jersey, USA
    Pediatr Blood Cancer 49:656-60. 2007
    ..Little is known about the effects of chemotherapy on patient antibody titers to vaccine-preventable infectious diseases; thus, there is no standard protocol for revaccinating post-chemotherapy patients...